TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Multiple Oral Doses Study Of PF-06427878 In Healthy Adult Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy male and/or female subjects of non childbearing potential.~* Body Mass Index (BMI) of 17.5 to 35.4 kg/m2; and a total body weight \>50 kg~* Subjects with fasting TG level of \>=90 mg/dL and \<=500 mg/dL following an overnight fast~* Subjects with low density lipoprotein cholesterol between 115 mg/dL and 190 mg/dL following an overnight fast~Exclusion Criteria:~•Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Cohort 1 (Type: EXPERIMENTAL): Single dose level of PF-06427878 at 5 mg or placebo every 8 hours (Q8H) for 14 days to investigate the safety, tolerability, and pharmacokinetics.
- Cohort 2 (Type: EXPERIMENTAL): Single dose level of PF-06427878 at a dose no more than 3.5-fold increase from Cohort 1 or placebo every 8 hours (Q8H) for 14 days to investigate the safety, tolerability, and pharmacokinetics.
- Cohort 3 (Type: EXPERIMENTAL): Single dose level of PF-06427878 at a dose no more than 3.5-fold increase from Cohort 2 or placebo every 8 hours (Q8H) for 14 days to investigate the safety, tolerability, and pharmacokinetics.
- Cohort 4 (Type: EXPERIMENTAL): Single dose level of PF-06427878 at a dose no more than 3.5-fold increase from Cohort 3 or placebo every 8 hours (Q8H) for 14 days to investigate the safety, tolerability, and pharmacokinetics.
- Cohort 5 (Type: EXPERIMENTAL): Single dose level of PF-06427878 at a dose no more than 3.5-fold increase from Cohort 4 or placebo every 8 hours (Q8H) for 14 days to investigate the safety, tolerability, and pharmacokinetics.
- Cohort 6 (Type: EXPERIMENTAL): Single dose level of PF-06427878 (with the same total daily dose as Cohort 5) or placebo every 12 hours (Q12H) for 14 days to investigate the safety, tolerability, and pharmacokinetics.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Anesthesia With Propofol, Dexmedetomidine and Lidocaine Infusions for Laparoscopic Cholecystectomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* American Society of Anesthesiologists I-II patients~* 20-60 years~Exclusion Criteria:~* American Society of Anesthesiologists III and above patients~* BMI: 35 and above~* Hepatic, renal or cardiac insufficiency~* 2 degree Heart block and above~* Diabetes~* Psychiatric disease~* History of chronic pain~* Alcohol or drug abuse~* Allergy to any of a drug in the study groups~* Pregnant, breast-feeding or menstruating women~* Inability to use a patient-controlled analgesia device~* Any analgesic or antiemetic use in last 24 hours before anesthesia induction~* Any surgical complication that may affect the outcomes of the study (open surgery etc.)

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Opiod-free group (Type: OTHER): Opioid-free anesthesia (Group DL) with dexmedetomidine (0.6 mg/kg loading, 0.3 mg/kg/h infusion), lidocaine (1.5 mg/kg loading, 2 mg/kg/h infusion), and propofol infusions (3-12 mg/kg/h).
- Opioid-based group (Type: OTHER): Opioid-based anesthesia (Group RF) with single dose fentanyl (2μg/kg), remifentanil (0.25μg/kg/min), and propofol infusions (3-12 mg/kg/h).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study To Evaluate An NK-1 Antiemetic For The Prevention Of Post Operative Nausea And Vomiting

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion criteria:~* Females age 18-55~* Laparoscopic/laparotomic gynecological procedure of laparoscopic gallbladder removal~Exclusion criteria:~* Pregnant or breastfeeding~* Post-menopausal~* Not undergoing general anesthesia

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Subcutaneous Daptomycin in Healthy Volunteers (DAPTOSC)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy volunteer from 18 to 65 years old~* Subject determined in good health by a doctor~* Signature of free and informed consent~* Affiliated to the French healthcare insurance~* Fluent in French~Exclusion Criteria:~* Active bacterial or viral infection~* Immunocompromised~* Body mass index \<20 or\> 30 kg / m2~* Kidney failure with glomerular filtration rate \<90ml / min / m2 calculated according to the CKD-EPI method~* Known or suspected liver disease~* Pregnant or lactating woman~* Guardianship or curators~* Any situation that could interfere with the self / hetero assessment of pain (dementia, psychiatric disorders, for example)~* Concomitant intake of myotoxic drugs (statins, fibrates, ciclosporin, for example)~* Allergy or known side effects to daptomycin~* Dermatological pathologies which may interfere with the subcutaneous injection (eczema, psoriasis, etc.)~* Localized tattoo or piercing on the abdomen which may interfere with the subcutaneous injection or the evaluation of possible local effects of the injection~* Parenteral exposure to daptomycin in the previous 30 days~* The inclusion of the subject in another interventional research protocol (during the present study and in the 3 months before inclusion).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Dapto SC-IV (Type: OTHER): First stage :~* Subcutaneous injection of daptomycin 10mg/kg~* Subcutaneous injection of placebo (physiological serum)~Second stage :~- Intravenous injection of daptomycin 10mg/kg
- Dapto IV-SC (Type: OTHER): First stage :~- Intravenous injection of daptomycin 10mg/kg~Second stage :~* Subcutaneous injection of daptomycin 10mg/kg~* Subcutaneous injection of placebo (physiological serum)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pregabalin for Treatment of Patients With Postherpetic Neuralgia (PHN)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female Chinese subjects, ages ≥18 at screening~* Subjects with symptoms of neuropathic pain associated with postherpetic neuralgia (PHN). Subjects must have pain present for ﹥3 months after healing of the acute herpes zoster skin rash~* At screening (V1), subjects must have a score ≥40mm on the 100-mm visual analog scale (VAS) of the Short Form-McGill Pain Questionnaire (SF-MPQ, see Appendix 3)~* At randomization (V2), subjects must have a score ≥40mm on the 100-mm visual analog scale (VAS) of the Short Form-McGill Pain Questionnaire (SF-MPQ, see Appendix 3)~* At randomization (V2), subjects must have completed at least 5 daily pain diaries (DPRS, see Appendix 2) and have an average daily pain score ≥4 over the past 7 days~Exclusion Criteria:~* Subjects who demonstrate a high response to placebo, with 30% decrease on the Pain Visual Analog Scale (VAS) at randomization as compared to screening~* Subjects who have a high variability in pain scores during the 1 week screening period, with any difference between two scores ﹥3

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Lyrica (pregabalin) (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Comparison of One Versus Two Doses of Influenza Vaccine in Children 5-8 Years of Age

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Immunocompetent children who are at least 5 and no more than 8 years of age on the date of the first vaccination.~* Parents able to give informed consent and child available for all study visits.~* Family able to understand and comply with planned study procedures.~* Family must have telephone accessibility.~Exclusion Criteria:~* Previous receipt of influenza vaccine of any kind (shot or nasal spray).~* Active cancer or blood system abnormalities such as leukemia.~* Immunocompromising illnesses or current receipt of immunosuppressive agents~* Allergy to eggs or egg protein, or to gentamicin (an antibiotic that is present in trace amounts in the vaccine).~* Any acute or chronic condition that (in the opinion of the investigator) would render vaccination unsafe or would interfere with the evaluation of responses.~Temporary Exclusion Criteria:~Acute disease, defined as the presence of moderate or severe illness with or without fever, at the time of enrollment. Influenza vaccine may be administered to children with minor illnesses, such as diarrhea, mild upper respiratory infection and low-grade febrile illness with an oral temperature \<100.4 F.

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 8 Years
- Healthy Volunteers: t

Study Arms:
- Subjects receiving vaccine (Type: EXPERIMENTAL): 2 0.5 ml doses of '04-05 Trivalent Influenza Vaccine 4 weeks apart.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Randomized, Double-Blinded Study of Simvastatin 20 mg/Day Versus Vytorin 10/20 in Subjects With Lipid Profiles Not Meeting Current NCEP Guidelines, Following a Low-Carbohydrate Diet

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2/PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Moderately obese with hyperlipidemia~Exclusion Criteria:~* Recent unstable heart or lung condition~* Current use of other lipid modifying drugs~* Hepatic disease~* Pregnancy or lactation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- 2 (Type: EXPERIMENTAL): Low carb diet plus simvastatin 20 mg/ezetimibe 10 mg

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Single Dose Study of Phentolamine Mesylate Eye Drops in Patients With Severe Night Vision Disturbances

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female patients ≥ 18 years of age~2. Currently experiencing severe night vision difficulty as reported subjectively~3. At least two patches below the normal range at any two frequencies in Contrast Sensitivity done under mesopic conditions with glare~4. Improvement in low contrast visual acuity (LCVA) in dim light during illumination of contralateral eye~5. Good general health~6. Written informed consent to participate in this trial~7. Ability to comply with all protocol mandated procedures and to attend all scheduled office visits~Exclusion Criteria:~1. Patients with untreated cataracts grades 1-4~2. Patients who wear contact lenses~3. Less than 5 weeks post-refractive surgery (LASIK or PRK)~4. Less than 5 weeks post intraocular lens insertion~5. Low blood pressure (systolic \<120 mm Hg or diastolic \<80 mm Hg)~6. A history of heart rate abnormalities~7. Administration of any investigational drug within 30 days of study initiation~8. Use of any eye drops with a pharmacologic effect on the pupil within 7 days of Visit 1~9. Use of any systemic alpha adrenergic antagonists (Appendix 1)~10. Known local or systemic hypersensitivity to adrenergic antagonists~11. For women of childbearing potential: currently pregnant or lactating, or unwilling to use birth control during the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Phentolamine Mesylate Ophthalmic Solution 1% (Type: EXPERIMENTAL): 1 drop in each eye (QD) for one day.
- Phentolamine Mesylate Ophthalmic Solution Vehicle (Type: PLACEBO_COMPARATOR): 1 drop in each eye (QD) for one day.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Celecoxib Versus Ibuprofen in the Treatment of Osteoarthritis of the Knee (Europe)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~Inclusion criteria:~* Aged \>=40 years old~* Diagnosed with OA of the knee according to the American College of Rheumatology and OA in flare state at baseline visit~* Functional capacity class of I-III~Exclusion Criteria:~Exclusion criteria:~* Inflammatory arthritis or gout or pseudo-gout with acute flare within the past 2 years (subjects with fibrositis or fibromyalgia will not be excluded)~* Acute joint trauma at index joint within the past 3 months with active symptoms~* Score of \>=20 on PHQ-9 or score of \>=1 on PHQ-9 item i~* Use of mobility assisting device for \<6 weeks or use of walker

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: ACTIVE_COMPARATOR): None
- C (Type: PLACEBO_COMPARATOR): None
- B (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Compare the Effect of ASP3550 With Goserelin in Patients With Prostate Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male patient with histologically confirmed prostate cancer (adenocarcinoma).~* Patient in whom endocrine treatment is indicated. Patient having undergoing prostatectomy or radiotherapy with curative intention and has a rising serum PSA (PSA ≥ 2 ng/mL at screening) may be included.~* Has a serum testosterone level above 2.2 ng/mL at screening.~* Has an Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) score of 0 to 2 at screening.~* Has a serum PSA ≥ 2 ng/mL at screening.~* Has a life expectancy of at least 12 months.~Exclusion Criteria:~* Previous or present endocrine treatment for prostate cancer. Example: surgical castration, GnRH agonists, GnRH antagonists, antiandrogens or oestrogens, and 5α-reductase inhibitors.~* Received a 5α-reductase inhibitor within 25 weeks preceding screening.~* Is a candidate for curative therapy, i.e., radical prostatectomy or radiotherapy within 12 months.~* Has concurrent or a history of poorly controlled severe asthma, anaphylactic reactions, severe urticaria or angioedema.~* Has hypersensitivity towards mannitol.~* Has a marked prolongation of QT/QTc interval (two consecutive increases to \>450 ms in QTc interval at retest) at screening.~* Has concurrent or a history of a disease (heart failure, hypokalemia, a family history of QT prolongation syndrome, etc.) that may induce Torsade de Pointes.

- Gender: MALE
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ASP3550 PART 1 and PART 2 (Type: EXPERIMENTAL): Part 1 for 1 year treatment and Part 2 for an extended period of treatment
- Goserelin (Type: ACTIVE_COMPARATOR): part 1 for 1 year treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: SCH-58500 in Treating Patients With Primary Ovarian, Fallopian Tube, or Peritoneal Cancer (C95084)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS: Radiographic or surgical evidence of primary ovarian, fallopian tube, or peritoneal carcinoma Ascites cytologically positive for peritoneal carcinomatosis from recurrent or persistent ovarian, fallopian tube, or peritoneal carcinoma Must have ascites and tumor accessible by laparoscopic or percutaneous biopsy Immunohistochemical evidence of p53 gene mutation in the ascitic fluid cell block or primary tumor biopsy or other documented mutation~PATIENT CHARACTERISTICS: Age: 18 and over Life expectancy: At least 3 months Performance status: Karnofsky 60-100% Hematopoietic: WBC at least 3,000/mm3 Absolute neutrophil count at least 1,000/mm3 Platelet count at least 100,000/mm3 Hepatic: Bilirubin less than 1.5 mg/dL AST/ALT less than 1.5 times the upper limit of normal (ULN) Alkaline phosphatase less than 1.5 times ULN Renal: Creatinine less than 1.5 mg/dL OR Creatinine clearance greater than 50 mL/min Other: Ability to tolerate paired paracenteses or biopsies (percutaneous or laparoscopic) HIV negative No adenoviral infections determined by ELISA screening No uncontrolled serious bacterial, viral, fungal or parasitic infection No known or suspected hypersensitivity to study drug or any excipient used in formulation or delivery system No underlying medical condition that would obscure interpretation of adverse events Not pregnant or nursing Fertile patients must use effective contraception for at least 1 month before, during, and 6 months after study~PRIOR CONCURRENT THERAPY: Biologic therapy: At least 1 month since prior biologic therapy and recovered Chemotherapy: At least 3 months since local intraperitoneal antitumor therapy directed against peritoneal carcinomatosis and recovered At least 1 month since systemic chemotherapy for ovarian, fallopian tube, or peritoneal cancer or an unapproved indication and recovered Endocrine therapy: At least 3 months since any systemic corticosteroid therapy Radiotherapy: At least 1 year since prior total abdominal radiotherapy Surgery: Not specified Other: At least 3 months since prior investigational therapy and recovered At least 3 months since prior immunosuppressive therapy

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Empagliflozin (BI 10773) in Type 1 Diabetes Mellitus Patients With or Without Renal Hyperfiltration

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria:~1. Male or female subjects 18 years of age or older diagnosed with type 1 diabetes mellitus~2. Glycated hemoglobin (HbA1C) of 6.5% to 11.0% and an estimated glomerular filtration rate (eGFR) greater or equal to 60 ml/min/1.73m² at screening~3. Subjects must be either experienced insulin pump users or be on multiple daily injections of any type of insulin~Exclusion criteria:~1. Evidence of macroalbuminuria or leukocyte positive urinalysis at screening~2. Any concomitant medication known to interfere with renin-angiotensin-aldosterone system (RAAS) activity or treatment with any other drugs to reduce blood glucose other than insulin~3. History of macrovascular disease or any other disease which would interfere with trial participation or any ongoing clinical condition that would jeopardize subject safety or study compliance based on investigator judgement

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- BI 10773 (Type: EXPERIMENTAL): Oral once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete